Home / Content / B2B Connect / Chemicals / Granules India receives 11 observations from Portuguese drug regulator

Granules India receives 11 observations from Portuguese drug regulator

Infarmed, Portugal, issued these observations for Granules India's Gagillapur facility

Granules India bags exclusive rights for USpharma Windlas' four products

premium

Last Updated : Jan 09 2017 | 4:38 PM IST

Granules India Ltd has received eleven observations from Infarmed, the Portuguese drug regulator, for its facility located at Gagillapur, Telangana. These observations were issued by Infarmed after it conducted a renewal inspection on the company's Gagillapur facility, which manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs).

“The company has initiated necessary and preventive action plan within the stipulated time. It will also be requesting the Infarmed for re-inspection of the Gagillapur facility at the earliest. The company is committed to comply with all the required regulatory requirements and follow the best practices of the industry. The company acknowledges the observations as area of continuous improvements,” said Granules India in a BSE filing on January 6, 2017.